[go: up one dir, main page]

MX2025009051A - Acidos pirazolo piperidin carboxilicos sustituidos - Google Patents

Acidos pirazolo piperidin carboxilicos sustituidos

Info

Publication number
MX2025009051A
MX2025009051A MX2025009051A MX2025009051A MX2025009051A MX 2025009051 A MX2025009051 A MX 2025009051A MX 2025009051 A MX2025009051 A MX 2025009051A MX 2025009051 A MX2025009051 A MX 2025009051A MX 2025009051 A MX2025009051 A MX 2025009051A
Authority
MX
Mexico
Prior art keywords
diseases
carboxylic acids
piperidine carboxylic
substituted pyrazolo
pyrazolo piperidine
Prior art date
Application number
MX2025009051A
Other languages
English (en)
Inventor
Arapinis Melissa Boultadakis
Lisa Candish
Marie- Pierre COLLIN-KRÖPELIN
Andre Dieskau
Lisa Dietz
Lucas Hudson Hofmeister
Ilka Mathar
Thomas Mondritzki
Hernandez Nuria Ortega
Peter Sandner
Carsten Schmeck
Timo Stellfeld
Alexandros Vakalopoulos
Robert Alan Webster
Frank Wunder
Original Assignee
Bayer Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Ag filed Critical Bayer Ag
Publication of MX2025009051A publication Critical patent/MX2025009051A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Psychiatry (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

La invención se refiere a ácidos pirazolo piperidin carboxílicos sustituidos, sus sales y a procesos para su preparación, y también a su uso para la preparación de medicamentos para el tratamiento y/o la profilaxis de enfermedades, en particular enfermedades cardiovasculares y cardíacas, preferiblemente insuficiencia cardíaca con fracción de eyección reducida y conservada (HFrEF, HFmrEF y HFpEF), hipertensión (HTN), enfermedades de arterias periféricas (PAD, PAOD), enfermedades cardiorrenales y renales, preferiblemente enfermedad renal crónica y diabética (CKD y DKD), enfermedades cardiopulmonares y pulmonares, preferiblemente hipertensión pulmonar (PH), y otras enfermedades, preferiblemente enfermedades neurodegenerativas y diferentes formas de demencias, enfermedades fibróticas, esclerosis sistémica (SSc), enfermedad de células falciformes (SCD), trastornos de cicatrización de heridas como la úlcera del pie diabético (DFU).
MX2025009051A 2020-12-10 2023-06-09 Acidos pirazolo piperidin carboxilicos sustituidos MX2025009051A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP20213016.7A EP4011873A1 (en) 2020-12-10 2020-12-10 Substituted pyrazolo piperidine carboxylic acids
PCT/EP2021/084980 WO2022122910A1 (en) 2020-12-10 2021-12-09 Substituted pyrazolo piperidine carboxylic acids

Publications (1)

Publication Number Publication Date
MX2025009051A true MX2025009051A (es) 2025-09-02

Family

ID=73793021

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2023006904A MX2023006904A (es) 2020-12-10 2021-12-09 Acidos pirazolo piperidin carboxilicos sustituidos.
MX2025009051A MX2025009051A (es) 2020-12-10 2023-06-09 Acidos pirazolo piperidin carboxilicos sustituidos

Family Applications Before (1)

Application Number Title Priority Date Filing Date
MX2023006904A MX2023006904A (es) 2020-12-10 2021-12-09 Acidos pirazolo piperidin carboxilicos sustituidos.

Country Status (19)

Country Link
US (3) US20220274958A1 (es)
EP (2) EP4011873A1 (es)
JP (1) JP7451700B2 (es)
KR (1) KR20230118145A (es)
CN (3) CN118787643A (es)
AR (1) AR124196A1 (es)
AU (2) AU2021393987A1 (es)
CA (1) CA3204491A1 (es)
CL (1) CL2023001633A1 (es)
CO (1) CO2023007334A2 (es)
CR (2) CR20250266A (es)
DO (1) DOP2023000114A (es)
EC (1) ECSP23041151A (es)
GE (2) GEAP202316286A (es)
IL (1) IL303299A (es)
MX (2) MX2023006904A (es)
PE (1) PE20231502A1 (es)
TW (1) TW202237588A (es)
WO (1) WO2022122910A1 (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4011874A1 (en) * 2020-12-10 2022-06-15 Bayer Aktiengesellschaft Substituted pyrazolo piperidine carboxylic acids
EP4011873A1 (en) * 2020-12-10 2022-06-15 Bayer Aktiengesellschaft Substituted pyrazolo piperidine carboxylic acids
WO2022122916A1 (en) * 2020-12-10 2022-06-16 Bayer Aktiengesellschaft Substituted pyrazolyl piperidine carboxylic acids
JP2025518350A (ja) 2022-06-09 2025-06-12 バイエル・アクチエンゲゼルシヤフト 女性における駆出率が維持された心不全の治療に使用するための可溶性グアニル酸シクラーゼアクチベーター
WO2024163561A1 (en) * 2023-01-31 2024-08-08 Invivosciences, Inc. Systems and methods for treating heart failure with preserved ejection fraction
WO2025067414A1 (zh) * 2023-09-27 2025-04-03 海思科医药集团股份有限公司 吡唑羧酸衍生物及其在医药上的应用
WO2025162280A1 (zh) * 2024-01-30 2025-08-07 海思科医药集团股份有限公司 吡唑羧酸衍生物及其在医药上的应用

Family Cites Families (63)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69928260T2 (de) 1998-07-08 2006-07-20 Sanofi-Aventis Deutschland Gmbh Schwefel-substituierte sulfonylaminocarbonsäure n-arylamide, ihre herstellung, ihre anwendung und diese enthaltende pharmazeutische zusammensetzungen
DE19830431A1 (de) 1998-07-08 2000-01-13 Hoechst Marion Roussel De Gmbh Sulfonylamino-carbonsäure-N-arylamide als Guanylatcyclase-Aktivatoren
DE19830430A1 (de) 1998-07-08 2000-01-13 Hoechst Marion Roussel De Gmbh Schwefelsubstituierte Sulfonylamino-carbonsäure-N-arylamide, ihre Herstellung, ihre Verwendung und sie enthaltende pharmazeutische Präparate
DE19834044A1 (de) 1998-07-29 2000-02-03 Bayer Ag Neue substituierte Pyrazolderivate
DE19834047A1 (de) * 1998-07-29 2000-02-03 Bayer Ag Substituierte Pyrazolderivate
DE19836697A1 (de) 1998-08-13 2000-02-17 Hoechst Marion Roussel De Gmbh Substituierte 4-Amino-2-aryl-pyrimidine, ihre Herstellung, ihre Verwendung und sie enthaltende pharmazeutische Präparate
GB9824310D0 (en) 1998-11-05 1998-12-30 Univ London Activators of soluble guanylate cyclase
DE19853278A1 (de) 1998-11-19 2000-05-25 Aventis Pharma Gmbh Substituierte 4-Amino-2-aryl-cyclopenta[d]pyrimidine, ihre Herstellung, ihre Verwendung und sie enthaltende pharmazeutische Präparate
WO2000046241A2 (en) 1999-02-08 2000-08-10 Zymogenetics, Inc. Prostate, testis and uterine polypeptide zpep14
DE19943636A1 (de) 1999-09-13 2001-03-15 Bayer Ag Neuartige Dicarbonsäurederivate mit pharmazeutischen Eigenschaften
DE19943639A1 (de) 1999-09-13 2001-03-15 Bayer Ag Dicarbonsäurederivate mit neuartigen pharmazeutischen Eigenschaften
DE19943635A1 (de) 1999-09-13 2001-03-15 Bayer Ag Neuartige Aminodicarbonsäurederivate mit pharmazeutischen Eigenschaften
DE19943634A1 (de) 1999-09-13 2001-04-12 Bayer Ag Neuartige Dicarbonsäurederivate mit pharmazeutischen Eigenschaften
DE19944226A1 (de) 1999-09-15 2001-03-29 Aventis Pharma Gmbh Verfahren zum Nachweis von oxidierten Formen der löslichen Guanylatzyklase und Verfahren zum Screening nach Aktivatoren der löslichen Guanylatzyklase mit oxidiertem Hämeisen
WO2001032604A1 (en) 1999-11-05 2001-05-10 University College London Activators of soluble guanylate cyclase
AR031176A1 (es) 2000-11-22 2003-09-10 Bayer Ag Nuevos derivados de pirazolpiridina sustituidos con piridina
DE10110749A1 (de) 2001-03-07 2002-09-12 Bayer Ag Substituierte Aminodicarbonsäurederivate
DE10110750A1 (de) 2001-03-07 2002-09-12 Bayer Ag Neuartige Aminodicarbonsäurederivate mit pharmazeutischen Eigenschaften
US20030016677A1 (en) 2001-07-17 2003-01-23 Karl Mauritz Fabric bus architeture
WO2003076408A2 (en) 2002-03-08 2003-09-18 Abbott Laboratories Indazole derivatives that are activators of soluble guanylate cyclase
EP1501605A1 (en) 2002-04-26 2005-02-02 ALTANA Pharma AG Novel use of guanylate cyclase activators for the treatment of respiratory insufficiency
DE10220570A1 (de) 2002-05-08 2003-11-20 Bayer Ag Carbamat-substituierte Pyrazolopyridine
US20040121994A1 (en) 2002-12-20 2004-06-24 Anderson Steven N. Novel amides that activate soluble guanylate cyclase
US20040192680A1 (en) 2002-12-20 2004-09-30 Anderson Steven N. Novel amides that activate soluble guanylate cyclase
GB0318094D0 (en) 2003-08-01 2003-09-03 Pfizer Ltd Novel combination
GB0325291D0 (en) 2003-10-29 2003-12-03 Pfizer Ltd Novel combination
KR20100059952A (ko) * 2007-09-06 2010-06-04 머크 샤프 앤드 돔 코포레이션 가용성 구아닐레이트 사이클라제 활성제
WO2009068652A1 (en) 2007-11-30 2009-06-04 Smithkline Beecham Corporation 2, 6-disubstituted pyridines and 2, 4-disubstituted pyrimidines as soluble guanylate cyclase activators
UY31507A1 (es) 2007-12-03 2009-07-17 Derivados de piridina activadores de guanilato ciclasa soluble
US8461348B2 (en) 2008-04-04 2013-06-11 Takeda Pharmaceutical Company Limited Heterocyclic derivative and use thereof
WO2010015652A2 (en) 2008-08-07 2010-02-11 Smithkline Beecham Corporation Thiazole compounds as activators of soluble guanylate cyclase
WO2010015653A1 (en) 2008-08-07 2010-02-11 Smithkline Beecham Corporation Pyrimidine derivatives as activators of soluble guanylate cyclase
WO2010065275A1 (en) 2008-11-25 2010-06-10 Merck Sharp & Dohme Corp. Soluble guanylate cyclase activators
WO2010099054A2 (en) 2009-02-26 2010-09-02 Merck Sharp & Dohme Corp. Soluble guanylate cyclase activators
DE102010001064A1 (de) 2009-03-18 2010-09-23 Bayer Schering Pharma Aktiengesellschaft Substituierte 2-Acetamido-5-Aryl-1,2,4-triazolone und deren Verwendung
US9187466B2 (en) 2010-02-27 2015-11-17 Bayer Intellectual Property Gmbh Bisaryl-bonded aryltriazolones and use thereof
WO2011115804A1 (en) 2010-03-17 2011-09-22 Ironwood Pharmaceuticals, Inc. Sgc stimulators
WO2011119518A1 (en) 2010-03-25 2011-09-29 Merck Sharp & Dohme Corp. Soluble guanylate cyclase activators
DE102010021637A1 (de) 2010-05-26 2011-12-01 Bayer Schering Pharma Aktiengesellschaft Substituierte 5-Fluor-1H-Pyrazolopyridine und ihre Verwendung
BR112012030177B1 (pt) 2010-05-27 2019-08-27 Merck Sharp & Dohme composto ativador da guanilato ciclase solúvel, e, composição farmacêutica
EP3173407A1 (en) 2010-06-30 2017-05-31 Ironwood Pharmaceuticals, Inc. Sgc stimulators
JP6114189B2 (ja) 2010-07-09 2017-04-12 バイエル・インテレクチュアル・プロパティ・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツングＢａｙｅｒ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ ＧｍｂＨ 縮合ピリミジンおよびトリアジンならびに心血管障害の処置および／または予防のためのその使用
DE102010040233A1 (de) 2010-09-03 2012-03-08 Bayer Schering Pharma Aktiengesellschaft Bicyclische Aza-Heterocyclen und ihre Verwendung
WO2012058132A1 (en) 2010-10-28 2012-05-03 Merck Sharp & Dohme Corp. Soluble guanylate cyclase activators
DE102010043379A1 (de) 2010-11-04 2012-05-10 Bayer Schering Pharma Aktiengesellschaft Substituierte 6-Fluor-1H-Pyrazolo[4,3-b]pyridine und ihre Verwendung
RU2016101964A (ru) 2010-11-09 2018-11-21 Айронвуд Фармасьютикалз, Инк. СТИМУЛЯТОРЫ sGC
EP2683710B1 (en) 2011-03-10 2017-07-19 Boehringer Ingelheim International GmbH Soluble guanylate cyclase activators
DE102011007272A1 (de) 2011-04-13 2012-10-18 Bayer Pharma Aktiengesellschaft Verzweigte 3-Phenylpropionsäure-Derivate und ihre Verwendung
MX2013014082A (es) 2011-05-30 2014-03-21 Astellas Pharma Inc Compuestos de imidazopiridina.
JP5826393B2 (ja) 2011-08-12 2015-12-02 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 可溶性グアニル酸シクラーゼ活性化因子
US9139564B2 (en) 2011-12-27 2015-09-22 Ironwood Pharmaceuticals, Inc. 2-benzyl, 3-(pyrimidin-2-yl) substituted pyrazoles useful as sGC stimulators
SI2892891T1 (sl) 2012-09-07 2019-11-29 Boehringer Ingelheim Int Alkoksi pirazoli kot topni aktivatorji gvanilat-ciklaze
WO2014047111A1 (en) 2012-09-18 2014-03-27 Ironwood Pharmaceuticals, Inc. Sgc stimulators
EP2897953B8 (en) 2012-09-19 2019-06-26 Cyclerion Therapeutics, Inc. Sgc stimulators
CN105531690B (zh) 2013-09-27 2018-11-09 英特尔公司 用于确定合适目标的方法、系统及存储介质
WO2015095515A1 (en) * 2013-12-20 2015-06-25 Novartis Ag Sgc activators for the treatment of glaucoma
BR112017009204A2 (pt) 2014-11-03 2018-07-03 Bayer Pharma Aktiengesellschaft Derivados de feniltriazol hidroxialquil- substituído e usos dos mesmos
TW202112359A (zh) 2019-06-07 2021-04-01 德商拜耳廠股份有限公司 sGC活化劑於治療眼科疾病之用途
HUE069255T2 (hu) * 2020-12-10 2025-02-28 Bayer Ag Szubsztituált pirazolo-piperidin-karbonsavak
WO2022122916A1 (en) * 2020-12-10 2022-06-16 Bayer Aktiengesellschaft Substituted pyrazolyl piperidine carboxylic acids
EP4011874A1 (en) * 2020-12-10 2022-06-15 Bayer Aktiengesellschaft Substituted pyrazolo piperidine carboxylic acids
EP4011873A1 (en) * 2020-12-10 2022-06-15 Bayer Aktiengesellschaft Substituted pyrazolo piperidine carboxylic acids
MX2023006902A (es) * 2020-12-10 2023-06-26 Bayer Ag Uso de activadores de sgc para el tratamiento de enfermedades oftalmologicas.

Also Published As

Publication number Publication date
CN118787643A (zh) 2024-10-18
GEP20247635B (en) 2024-06-25
AU2021393987A9 (en) 2025-04-03
MX2023006904A (es) 2023-06-26
CO2023007334A2 (es) 2023-06-09
US12195448B2 (en) 2025-01-14
IL303299A (en) 2023-07-01
GEAP202316286A (en) 2023-09-11
EP4011873A1 (en) 2022-06-15
KR20230118145A (ko) 2023-08-10
AU2021393987A1 (en) 2023-06-22
CR20230238A (es) 2023-07-19
WO2022122910A1 (en) 2022-06-16
AU2025279820A1 (en) 2026-01-15
CR20250266A (es) 2025-08-27
TW202237588A (zh) 2022-10-01
US20220274958A1 (en) 2022-09-01
JP7451700B2 (ja) 2024-03-18
DOP2023000114A (es) 2023-07-09
US20230265072A1 (en) 2023-08-24
CA3204491A1 (en) 2022-06-16
CN114981257A (zh) 2022-08-30
PE20231502A1 (es) 2023-09-26
EP4259615A1 (en) 2023-10-18
CN118791463A (zh) 2024-10-18
JP2023543646A (ja) 2023-10-18
CN114981257B (zh) 2024-07-05
CL2023001633A1 (es) 2023-11-10
US20250026737A1 (en) 2025-01-23
AR124196A1 (es) 2023-02-22
ECSP23041151A (es) 2023-07-31

Similar Documents

Publication Publication Date Title
MX2025009051A (es) Acidos pirazolo piperidin carboxilicos sustituidos
CR20230242A (es) Ácidos pirazol piperidin carboxílicos sustituidos
JP2019521976A5 (es)
Cartotto et al. Vasopressin for the septic burn patient
Santoro Heart failure and cardiorenal syndrome in the elderly
Akhtar et al. Cardiac tamponade on ECPELLA: a case report of a unique hemodynamic picture
Li et al. Successful cardiopulmonary cerebral resuscitation in patient with severe acute pancreatitis
Kraiem et al. P4718 Follow up in heart failure center versus routine practice: which positive impact we can have?
SAITOH et al. Effects of let ventricular systolic dysfunction and cardio-renal anemia syndrome on walking ability and Activities of Daily Living in patients with heart failure
Shah et al. Isolated cor-triatriatum sinister presenting as new onset atrial-fibrillation in a 53-year-old female
Dres et al. Impact of Diaphragmatic Dysfunction on Cardiac Function and Lung Aeration During Weaning from Mechanical Ventilation
Ruopp et al. Against All Odds: A Case of Severe Pulmonary Hypertension Secondary to Concomitant PiSZ Alpha-1-Antitrypsin Deficiency and Combined Pulmonary Fibrosis and Emphysema Successfully Treated with Intravenous Epoprostenol
Lang et al. Pulmonary Artery Endovascular Device to Improve Vascular Compliance in Pulmonary Hypertension
Haque et al. Clinical Response of Enhanced External Counter Pulsation (EECP) Among Bangladeshi Ischemic Heart Disease Patients
Lapanashvili et al. Acute Beneficial Effects of Muscular Counterpulsation in Patients with Coronary Heart Diseases
Towers et al. Complete heart block in young people
RU2004105673A (ru) Способ оценки тяжести хронической сердечной недостаточности
Fang Device Therapy for Heart Failure
Pardaens Physiological and psychosocial factors influencing exercise capacity and exercise training in cardiac patients
Zeng et al. Sequential mechanical ventilation improves hemodynamics, cardiac function and neurohumoral status in elderly patients with acute left heart failure
Veerbhadran Intractable hyperkalaemia and cardiac arrest: case report
Pilato Pulmonary embolism: case report
Takada et al. Triglyceride Deposit Cardiomyovasculopathy with Severe Heart Failure
Nagata et al. A Case of Patient Suspected Familial Dilated Cardiomyopathy with Conduction Abnormality
Yoon Cisatracurium besilate